BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
One major comment involves your overselling of the 2 kg weight difference. These people weigh perhaps 85-90 kg prior to treatment, and losing an estimated 2 kg more (than if they had received sulf's) is really not an important improvement. It's statistically significant, but not clinically important. I suspect neither nor NICE nor FDA would consider 2% of body weight to be a clinically important weight difference. So I would say your revision should call this a clinically unimportant difference. I myself would even go so far as to say the two types of drugs result in "similar" weight even though the large numbers of patients resulted in a statistically significant difference. But probably you and I could meet in the middle to simply say that it's statistically significant and clinically unimportant.
I suspect you will get complaints from other reviewers that you did not examine the safety data. You have been clear about this in the document (both in the intro and the discussion)…the question is whether this is a responsible choice on your part. I suppose the risk is that a naïve reader will forget to consider safety. But the audience is mostly clinicians, who obviously will not forget that, so I think you are OK. The only thing I might suggest is to present the existing safety data from your references 9-11 in the introduction, so at least the established data are there.
Fixed effects models are hard to justify both philosophically and practically. Philosophically, it seems hard to believe that any two studies' TRUE effect sizes are the same. Differences in patient enrollment, design, follow-up etc. seem that they would inevitably be attempting to estimate at least slightly different things. Practically, if there is no heterogeneity in results, then the random effect model will give you the same CI as the fixed effects, and if there is heterogeneity in results, even a little, then only the random effect estimate will widen appropriately, in order to incorporate that heterogeneity. So MINOR COMMENTS Throughout: The authors say "observational studies" but I think better would be "non-randomized studies". You need a phrases that creates a true dichotomy with "RCT"s, and that phrase is non-randomized studies. The Cochrane handbook uses it.
Throughout: there are some problematic phrases such as "no difference was observed". I assume this phrasing is based on statistical non-significance. Which always begs the question of whether the CI is narrow enough to conclude that there is no important difference. I encourage you to be more direct by following your wording of "…suggested similar..." in the abstract.
Methods section of Abstract didn't list microvascular/macrovascular complications, but if you had seen that data you would have included it, so it was considered in your methods.
Abstract, first sentence of conclusions. This of course is the most important sentence in the entire review. Please change "significant" to "similar", since few would agree with you that 2 kg in a 90 kg person is "significant". And the second sentence could be more straightforward to say "Other outcomes also showed similarity between the two drugs' effects".
Methods, eligibility criteria. For HbA1c, you should have set a minimum followup of 3 months. If you did, say that here. If not, why not?
Under data extraction, you said you used reported intention to treat analyses where possible. The problem with ITT is that it can bias the analysis in favor of equivalence. See Section F of https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulato ryInformation/Guidances/UCM202140.pdf It's particularly true when there is switching amongst treatments (ie any real treatment differences are washed out by some patients getting both treatments but only analyzed as originally assigned). Anyway, the sentence made me wonder the extent to which your various findings of noimportant-difference had been due to ITT approaches. This should be discussed as a possible limitation in your discussion section. You might also, if time, consider an as-treated approach as a secondary analysis. If those also show clearly no important difference, then the primary analyses were clearly not due to ITT.
Overlapping patient populations. Can you give the reader a sense for how big a problem this was? Since it artificially narrows the CIs via double-counting.
Tau is a more direct measure of heterogeneity than I2. See the article by Rucker in BMC Med Res Methodol 8(1) p79. The problem with I2 is that it depends on the Ns. Try it yourself: take a metaanalysis and look at I2. Now triple the Ns, but keep all the effect sizes the same. See how I2 increased? Yeah. That's not good. Note that tau would not have increased, since it more purely measures the extent to which effect sizes differed.
The meta-analytic method of Dersimonian and Laird has lately been criticized for producing 95% confidence intervals that are really too narrow, they are more like 85% confidence intervals (based on simulations). See the article by Steve Goodman and colleagues, see Ann Intern Med. 2014; 160:267-270) . Also see the simulation article by Kontopantelis in Stat Methods Med Res. 2012 Aug; 21(4):409-26. Two random-effects methods that are better than D&L KnappHartung and profile likelihood, and they provide more accurate confidence intervals.
The Kim RCT had a rather glaring baseline difference in FPG (7.3 vs 8.7) as well as diabetes duration (4.8 years vs 5.9 years) and gender (75% male vs 41%). Wouldn't you think the trial would be biased against sulf? At least you should draw the reader's attention to this potential issue. It was a tiny trial N=17 per group, maybe just got unlucky with the group assignments.
For the nonrandomized studies, I would have really appreciated a paragraph on the types of controls for confounding that the studies tried to use. Which variables were controlled for? And how? Propensity scoring? Instrumental variables? Other magical potions? Maybe you did discuss this and I missed it. Figure 1 says that 12 studies were "included in quantitative synthesis". Please check this for accuracy. Figure 2 , panel D. Are you sure that the "favours sita" and "favours self" are placed correctly? As I read it, the outcome is the % of patients who achieved <7% A1c. So it's a good thing to have an event. Now take the Arech trial. The success rate was 52% with sita compared to 60% with sulf. And yet the plot indicates that the data favor sita? Same point for all the other plots in panel D. Also check this in Figure 3E , Figure 3F , and your supplemental figures. The manuscript is well written; and might be informative to general readers of the journal.
Thank you, please find responses below to individual comments.
SPECIFIC COMMENTS FROM REVIEWER 1:
1. DPP-4i enhances insulin secretion glucose-dependently and improves glycemic control with reduced hypoglycemia risks. As described previously, this is one of the advantage of using DPP-4i compared to SU, especially among the elderly and those with renal impairment (e.g., PMID: 28294488).
The authors should perform comparison of hypoglycemia using the same data sets.
Thank you very much for highlighting this reference and raising this important point. We agree that consideration of safety aspects of treatments is crucial to any treatment decision-making process. However, the lower risk of hypoglycaemia with sitagliptin and indeed other DPP-4i has been extensively studied as per citation above, in meta-analyses and well recognised in all national and international guidelines. We did not believe there was a need to re-analyse this information but rather summarise it succinctly for our readers.
The aim of this systematic review was to study effectiveness and not adverse effects because they have been extensively explored as per above. We had originally comprehensively summarised the safety literature in our discussion but we appreciate your point of how important safety aspects are, hence we have now moved this section to the introduction, to the forefront of this manuscript and detailed it in depth. Please see below: 
Though safety of both treatments has been well evaluated, less has been characterized about the comparative effectiveness of sitagliptin compared to sulphonylureas from both randomized controlled trials (RCT) and nonrandomized studies using "real world" data."
Also within the strengths and limitations box, we now state that this review focused only on effectiveness as this is an area where we are more uncertain with respect to these two treatments, however safety literature has been evaluated in considerable depth in other meta-analyses and we have cited and summarised their work in detail. We agree that this weight reduction with sitagliptin is modest and in fact the difference is driven by an approx. 1kg increase in weight with sulphonylureas and approx. 1kg decrease in weight with sitagliptin. We agree this may not be of huge clinical consequence for most patients in the 85-100kg, however can be of greater interest in patients at greater extremes of weight e.g frail elderly patients or those struggling to lose weight which of course can be key to controlling the diabetes.
Strengths and Limitations
We have revised the manuscript entirely to reflect the above more clearly and to not overstate the significance of this comparative weight loss. 2.I suspect you will get complaints from other reviewers that you did not examine the safety data. You have been clear about this in the document (both in the intro and the discussion)…the question is whether this is a responsible choice on your part. I suppose the risk is that a naïve reader will forget to consider safety. But the audience is mostly clinicians, who obviously will not forget that, so I think you are OK. The only thing I might suggest is to present the existing safety data from your references 9-11 in the introduction, so at least the established data are there.
Thanks you for your suggestion, we agree that safety in any treatment decision is of great importance. However as we have highlighted in our references and safety summary, we felt that this is an area that has been very extensively studied and clinicians are familiar with. We felt the gap existed in relation to effectiveness and hence our systematic review, as you highlighted, has focused entirely on this.
Nevertheless, though most clinicians may be familiar with this information, we agree that the safety literature is very important and would be better placed in the introduction, in the forefront of the manuscript for all readers as follows: Also within the strengths and limitations box, we once again state that this review focused only on effectiveness as this is an area where we are more uncertain with respect to these two treatments. However, safety literature has been evaluated in considerable depth in other meta-analyses and we have cited and summarised their work in detail in the introduction. In doing so, we believe we are being fully transparent with any reader of the manuscript about the goal of this manuscript while also providing a summary of the safety literature. We understand that use of fixed effects models for analysis alone can be controversial for the exact reasons you have highlighted. However in our study, the three RCTs meta-analysed across the 4 outcomes of interest exhibited negligible heterogeneity. In fact, the fixed effects and random effects analysis, much like you stated, yielded identical results. (Please see our response to comment 9 below for further detail around this point and the estimates obtained).

MINOR COMMENTS
1. Throughout: The authors say "observational studies" but I think better would be "non-randomized studies". You need a phrases that creates a true dichotomy with "RCT"s, and that phrase is nonrandomized studies. The Cochrane handbook uses it.
We agree use of "non-randomized studies" is better terminology and have amended throughout manuscript. We have made changes throughout as needed and consistently used "suggested similar.."
Methods section of Abstract didn't list microvascular/macrovascular
complications, but if you had seen that data you would have included it, so it was considered in your methods.
Yes that was our intention. We have moved the fact we found no data on micro-and macro-vascular complications from the abstract results to abstract methods to highlight this more clearly. Intention to Treat analyses when there is substantial drop out can indeed bias results towards the null however this was not the case across studies included. Moreover the aim of this review was not to obtain a precise estimate of efficacy which has already been examined but to help shed further light on effectiveness or use in "real world" practice (focusing on the initial prescribing decision) and hence for this purpose the ITT analysis was deemed most appropriate.
ABSTRACT: METHODS AND ANALYSES
We agree this is an important discussion point and have added below: We have added in a sentence in Figure 2 and Supplementary Figures S1 and S2 in our appendix to make the reader aware that we have analysed our data with both fixed and random effects analysis and found no difference Thanks, we have highlighted this more clearly in the bias assessment as below and expanded this section to make explicit the faults in this study and explain why we could not use the study data for analysis.
